New Drug Product: Durysta
This slideshow shows drug information for Durysta. Click here for the complete Durysta monograph.
Glaucoma
Glaucoma Patients Worry About Managing Disease During Pandemic
Delayed or canceled appointments during lockdown causing the greatest concern.
Durysta Approved for Open-Angle Glaucoma, Ocular Hypertension
The Food and Drug Administration (FDA) has approved Durysta (bimatoprost implant; Allergan) for the reduction of intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension.
Sepetaprost Effective and Safe in Glaucoma, Ocular Hypertension
This article is part of MPR’s coverage of the American Academy of Ophthalmology 2019 Meeting, taking place in San Francisco, CA. Our staff will report on medical research related to eye disorders, conducted by experts in the field. Check back regularly for more news from AAO 2019. SAN FRANCISCO – Sepetaprost 0.002% was found to…
Prostaglandin Analogues Compared for Open-Angle Glaucoma, Ocular Hypertension
Latanoprostene bunod showed greater reduction in intraocular pressure (IOP) after 3 months compared to other treatments for open-angle glaucoma and ocular hypertension.
Netarsudil Lowers IOP in Glaucoma, Ocular Hypertension
ROCKET-4 study shows once-daily netarsudil noninferior to twice-daily timolol
FDA to Review Bimatoprost SR Implant for IOP Reduction in Glaucoma, Ocular HTN
The Food and Drug Administration (FDA) has accepted for review the New Drug Application (NDA) for bimatoprost sustained-release (SR; Allergan), a first-in-class biodegradable implant, for the reduction of intraocular pressure (IOP) in patients with primary open-angle glaucoma or ocular hypertension. The NDA includes data from two phase 3 studies (NCT02250651, NCT02247804) that evaluated the efficacy…
Longer Duration of Statin Use Linked to Lower Risk for Glaucoma
Self-reported high cholesterol levels without statin use tied to higher glaucoma risk
Rocklatan Approved to Reduce IOP in Patients With Open-Angle Glaucoma or Ocular Hypertension
The Food and Drug Administration (FDA) has approved Rocklatan (netarsudil 0.02% and latanoprost 0.005% ophthalmic solution; Aerie) for the reduction of elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension.
Xelpros Approved for Open-Angle Glaucoma, Ocular Hypertension
Xelpros contains latanoprost, a prostaglandin F2α analogue that is believed to reduce IOP by increasing the outflow of aqueous humor.
